Granted Patent
B2
US 12,268,697 · App. 18/603,816 · Granted Apr 8, 2025
Oxysterols and methods of use thereof
Inventors:
Francesco G. Salituro (Marlborough, MA); Albert Jean Robichaud (Boston, MA); Gabriel Martinez Botella (Wayland, MA)
Assignee:
Sage Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R 1 , R 2 , R 3 , R 6 , R 7 , R 8 , and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
Claims (4)
1. A compound having the structure
2. A pharmaceutically acceptable salt of the compound:
3. A pharmaceutical composition comprising the compound according to claim 1 , and a pharmaceutically acceptable carrier.
4. A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound according to claim 2 , and a pharmaceutically acceptable carrier.
Assignments (3)
CHANGE OF NAME
Recorded Mar 17, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075171/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 6, 2025
From: SALITURO, FRANCESCO G.; ROBICHAUD, ALBERT JEAN; BOTELLA, GABRIEL MARTINEZ
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071341/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 6, 2025
From: SALITURO, FRANCESCO G.; ROBICHAUD, ALBERT JEAN; BOTELLA, GABRIEL MARTINEZ
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071341/0875 →
Continuity (6)
Continuation
15742425
Provisional Application
62280394
· Jan 19, 2016
Provisional Application
62189048
· Jul 6, 2015
References Cited (379)
US 2259698A
· Johannessohn et al.
· 1941
[cited by applicant]
US 2594323A
· Levin et al.
· 1952
[cited by applicant]
US 2673206A
· Ryer
· 1954
[cited by applicant]
US 3079385A
· Bertin et al.
· 1963
[cited by applicant]
US 3206459A
· Cross
· 1965
[cited by applicant]
US 4071625A
· Grunwell et al.
· 1978
[cited by applicant]
US 4174345A
· Kaiser
· 1979
[cited by applicant]
US 4183852A
· Kaiser
· 1980
[cited by applicant]
US 4358406A
· De Luca et al.
· 1982
[cited by applicant]
US 4868165A
· Ikekawa
· 1989
[cited by applicant]
US 5232917A
· Bolger et al.
· 1993
[cited by applicant]
US 5376645A
· Stella et al.
· 1994
[cited by applicant]
US 5512570A
· Dorn et al.
· 1996
[cited by applicant]
US 5595996A
· Graham et al.
· 1997
[cited by applicant]
US 5843953A
· Tolman et al.
· 1998
[cited by applicant]
US 5888996A
· Farb
· 1999
[cited by applicant]
US 5925630A
· Upasani et al.
· 1999
[cited by applicant]
US 6407086B2
· Faarup et al.
· 2002
[cited by applicant]
US 6645953B2
· Gronvald et al.
· 2003
[cited by applicant]
US 6884796B2
· Faarup et al.
· 2005
[cited by applicant]
US 6933312B2
· Price et al.
· 2005
[cited by applicant]
US 8034798B2
· Baulieu et al.
· 2011
[cited by applicant]
US 8247436B2
· Baettig et al.
· 2012
[cited by applicant]
US 8604011B2
· Mellon
· 2013
[cited by applicant]
US 8673843B2
· Moskal et al.
· 2014
[cited by applicant]
US 8829213B2
· Peng et al.
· 2014
[cited by applicant]
US 20040048838A1
· Gronvald et al.
· 2004
[cited by applicant]
US 20050101573A1
· Faarup et al.
· 2005
[cited by applicant]
US 20060142241A1
· Yoo
· 2006
[cited by applicant]
US 20070032464A1
· Lia et al.
· 2007
[cited by applicant]
US 20100087411A1
· Barraclough et al.
· 2010
[cited by applicant]
US 20110160223A1
· Dingledine et al.
· 2011
[cited by applicant]
US 20110190249A1
· Rees et al.
· 2011
[cited by applicant]
US 20120035156A1
· Alberati et al.
· 2012
[cited by applicant]
US 20120040916A1
· Moon et al.
· 2012
[cited by applicant]
US 20130210792A1
· Song et al.
· 2013
[cited by applicant]
US 20140045943A1
· Khan et al.
· 2014
[cited by applicant]
US 20140148412A1
· Hogenkamp
· 2014
[cited by applicant]
US 20140335050A1
· Haggerty et al.
· 2014
[cited by applicant]
US 20150158903A1
· Upasani et al.
· 2015
[cited by applicant]
US 20150291654A1
· Upasani et al.
· 2015
[cited by applicant]
US 20150376225A1
· Dugar et al.
· 2015
[cited by applicant]
US 20160022701A1
· Reddy et al.
· 2016
[cited by applicant]
US 20160031930A1
· Botella et al.
· 2016
[cited by applicant]
US 20170304321A1
· Quirk et al.
· 2017
[cited by applicant]
US 20170305960A1
· Botella et al.
· 2017
[cited by applicant]
US 20190160078A1
· Masuoka et al.
· 2019
[cited by applicant]
US 20190233465A1
· Robichaud et al.
· 2019
[cited by applicant]
US 20190330259A1
· Robichaud et al.
· 2019
[cited by applicant]
US 20210040138A1
· Harrison et al.
· 2021
[cited by applicant]
US 20210101925A1
· Salituro et al.
· 2021
[cited by applicant]
US 20210145848A1
· Salituro et al.
· 2021
[cited by applicant]
US 20210147470A1
· Upasani et al.
· 2021
[cited by applicant]
US 20240252514A1
· Doherty et al.
· 2024
[cited by applicant]
CN 1257077
· 2000
[cited by applicant]
CN 1254716
· 2008
[cited by applicant]
FR 2850023
· 2004
[cited by applicant]
GB 1564806
· 1980
[cited by applicant]
JP 50140435
· 1975
[cited by applicant]
JP 53082766
· 1978
[cited by applicant]
JP 54163565
· 1979
[cited by applicant]
JP 57035597
· 1982
[cited by applicant]
JP 61254599
· 1986
[cited by applicant]
JP 62187485
· 1987
[cited by applicant]
JP 08268917
· 1996
[cited by applicant]
JP 09328498
· 1997
[cited by applicant]
JP H11509844A
· 1999
[cited by applicant]
JP 2009545535
· 2009
[cited by applicant]
JP 2016514967
· 2016
[cited by applicant]
RU 2194712C2
· 2002
[cited by applicant]
RU 2458065C2
· 2012
[cited by applicant]
WO WO1980002562
· 1980
[cited by applicant]
WO WO1989002272
· 1989
[cited by applicant]
WO WO1994027608
· 1994
[cited by applicant]
WO WO1995002409
· 1995
[cited by applicant]
WO WO1995013287
· 1995
[cited by applicant]
WO WO1995021617
· 1995
[cited by applicant]
WO WO1996012705
· 1996
[cited by applicant]
WO WO1996016076
· 1996
[cited by applicant]
WO WO1996040043
· 1996
[cited by applicant]
WO WO1996040151
· 1996
[cited by applicant]
WO WO1997000884
· 1997
[cited by applicant]
WO WO1997003677
· 1997
[cited by applicant]
WO WO1997042215
· 1997
[cited by applicant]
WO WO1998005337
· 1998
[cited by applicant]
WO WO1998007740
· 1998
[cited by applicant]
WO WO1999058497
· 1999
[cited by applicant]
WO WO2000063228
· 2000
[cited by applicant]
WO WO2000066614
· 2000
[cited by applicant]
WO WO2000068246
· 2000
[cited by applicant]
WO WO2001049703
· 2001
[cited by applicant]
WO WO2002011708
· 2002
[cited by applicant]
WO WO2002053577
· 2002
[cited by applicant]
WO WO2002079221
· 2002
[cited by applicant]
WO WO2002090375
· 2002
[cited by applicant]
WO WO2003039480
· 2003
[cited by applicant]
WO WO2003049685
· 2003
[cited by applicant]
WO WO2003082893
· 2003
[cited by applicant]
WO WO2004055201
· 2004
[cited by applicant]
WO 2005037287A1
· 2005
[cited by applicant]
WO WO2005079810
· 2005
[cited by applicant]
WO WO2008041003
· 2008
[cited by applicant]
WO WO2008063128
· 2008
[cited by applicant]
WO WO2009001097
· 2008
[cited by applicant]
WO WO2009059961
· 2009
[cited by applicant]
WO WO2009073186
· 2009
[cited by applicant]
WO WO2009090063
· 2009
[cited by applicant]
WO WO2010075282
· 2010
[cited by applicant]
WO WO2010088414
· 2010
[cited by applicant]
WO WO2011014661
· 2011
[cited by applicant]
WO WO2011028794
· 2011
[cited by applicant]
WO WO2011067501
· 2011
[cited by applicant]
WO WO2011092127
· 2011
[cited by applicant]
WO WO2012064501
· 2012
[cited by applicant]
WO WO2012142039
· 2012
[cited by applicant]
WO WO2013019711
· 2013
[cited by applicant]
WO 2013036835A1
· 2013
[cited by applicant]
WO WO2013054822
· 2013
[cited by applicant]
WO WO2013056181
· 2013
[cited by applicant]
WO WO2013163455
· 2013
[cited by applicant]
WO WO2014025942
· 2014
[cited by applicant]
WO WO2014115167
· 2014
[cited by applicant]
WO WO2014120786
· 2014
[cited by applicant]
WO WO2014160441A1
· 2014
[cited by examiner]
WO WO2014160480
· 2014
[cited by applicant]
WO WO2015048316
· 2015
[cited by applicant]
WO WO2015120280
· 2015
[cited by applicant]
WO WO2015195967
· 2015
[cited by applicant]
WO WO2016007762
· 2016
[cited by applicant]
WO WO2016057713
· 2016
[cited by applicant]
WO WO2017007832
· 2017
[cited by applicant]
WO WO2017007836
· 2017
[cited by applicant]
WO WO2017007840
· 2017
[cited by applicant]
WO WO2017037465
· 2017
[cited by applicant]
WO WO2017173358
· 2017
[cited by applicant]
WO WO2018064649
· 2018
[cited by applicant]
WO WO2018075698
· 2018
[cited by applicant]
WO WO2018075699
· 2018
[cited by applicant]
WO WO2018170336
· 2018
[cited by applicant]
WO 2022261510A1
· 2022
[cited by applicant]
Berardelli et al., “EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease,” European Journal of Neurology, 20(1):16-34 (2013).
[cited by applicant]
Berge et al., “Pharmaceutical salts,” Journal of Pharmaceutical Sciences, 66(1):1-19 (1977).
[cited by applicant]
Bjorkhem et al., “Oxysterols in the circulation of patients with the Smith-Lemli-Opitz syndrome: abnormal levels of 24S- and 27-hydroxycholesterol,” Journal of Lipid Research, 42(3):366-371 (2001).
[cited by applicant]
Bukelis et al., “Smith-Lemli-Opitz syndrome and autism spectrum disorder,” American Journal of Psychiatry, 164(11):1655-1661 (2007).
[cited by applicant]
Cais et al., “Temperature dependence of NR1/NR2B NMDA receptor channels,” Neuroscience, 151(2):428-438 (2008).
[cited by applicant]
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/ cancer.html> (11 pages).
[cited by applicant]
Chen et al., “The chemical biology of clinically tolerated NMDA receptor antagonists,” Journal of Neurochemistry, 97(6):1611-1626 (2006).
[cited by applicant]
Citraro et al., “Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy,” Neuropharmacology, 50(8):1059-1071 (2006).
[cited by applicant]
Collingridge et al., “The NMDA receptor as a target for cognitive enhancement,” Neuropharmacology, 64:13-26 (2013).
[cited by applicant]
Connick et al., “Program No. 613 1/B86,” 2009 Neuroscience Meeting Planner, Chicago, IL: Society for Neuroscience (2009) (2 pages).
[cited by applicant]
Cook et al., “24-hydroxycholesterol sulfation by human cytosolic sulfotransferases: formation of monosulfates and disulfates, molecular modeling, sulfatase sensitivity, and inhibition of liver X receptor activation,” Dr…
[cited by applicant]
Corman et al., “Structure-activity relationships for side chain oxysterol agonists of the hedgehog signaling pathway,” ACS Medicinal Chemistry Letters, 3(10):828-833 (2012).
[cited by applicant]
Costa et al., “A novel family of negative and positive allosteric modulators of NMDA receptors,” Journal of Pharmacology and Experimental Therapeutics, 335(3):614-621 (2010).
[cited by applicant]
Cross et al., “Steroids CCLXXIN
[cited by applicant]
Dale et al., “Nuclear magnetic resonance enantiomer regents. Configurational correlations via nuclear magnetic resonance chemical shifts of diastereomeric mandelate, O-methylmandelate, and .alpha.-methoxy-.alpha.-triflu…
[cited by applicant]
Dayal et al., “Stereospecific synthesis of 3 beta-hydroxylated bile alcohols,” Journal of Lipid Research, 25(6):646-650 (1984).
[cited by applicant]
Deng et al., “Fluoro analogs of bioactive oxy-steroids: Synthesis of an EBI
[cited by applicant]
Domasio, “Alzheimer's disease and related dementias,” Cecil Textbook of Medicine, 20th edition, 2:1992-1996 (1996).
[cited by applicant]
Dubois et al., “Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria,” Lancet Neurology, 6(8):734-746 (2007).
[cited by applicant]
Dubois et al., “Revising the definition of Alzheimer's disease: a new lexicon,” Lancet Neurology, 9(11):1118-27 (2010).
[cited by applicant]
EESR for European Application No. 14774060.9, dated Aug. 17, 2016 (11 pages).
[cited by applicant]
EESR for European Application No. 14775126.7, dated Sep. 14, 2016 (7 pages).
[cited by applicant]
EESR for European Application No. 14775126.7, Dec. 15, 2016 (7 pages).
[cited by applicant]
EESR for European Application No. 15809462.3, dated Nov. 29, 2017 (8 pages).
[cited by applicant]
EESR for European Application No. 15849514.3, dated May 23, 2018 (7 pages).
[cited by applicant]
EESR for European Application No. 16821920.2, dated Jan. 31, 2019 (12 pages).
[cited by applicant]
EESR for European Application No. 16821924.4, dated Jan. 31, 2019 (12 pages).
[cited by applicant]
EESR for European Application No. 16821926.9, dated Jan. 31, 2019 (10 pages).
[cited by applicant]
Elbarbry et al., “Cyclosporine-induced changes in drug metabolizing enzymes in hyperlipemic rabbit kidneys could explain its toxicity,” Xenobiotica, 40(11):772-781 (2010).
[cited by applicant]
FDA mulls drug to slow late-stage Alzheimer's [online] (cnn.com/health), [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL; http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/indexhtml> (2 p…
[cited by applicant]
Ferriz et al., “Prodrug Design of Phenolic Drugs”, Current Pharmaceutical Designs 16: 2033-2052 (2010).
[cited by applicant]
Festa et al., “Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR
[cited by applicant]
Foster et al., “Effect of steroids on beta-adrenoceptor-mediated relaxation of pig bronchus,” British Journal of Pharmacology, 78(2):441-445 (1983).
[cited by applicant]
Fukuto et al., “Determination of the Mechanism of Demethlenation of (methylenedioxy)phenyl compounds by cytochrome P450 using deuterium isotope effects,” Journal of Medicinal Chemistry, 34(9):2871-2876 (1991).
[cited by applicant]
Gee et al., “GABA-dependent modulation of the C1-ionophore by steroids in rat brain,” European Journal of Pharmacology, 136(3):419-423 (1987).
[cited by applicant]
Golub et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring,” Science, 286(5439):531-537 (1999).
[cited by applicant]
Groden et al., “Determination of Fura-2 dissociation constants following adjustment of the apparent Ca-EGTA association constant for temperature and ionic strength,” Cell Calcium, 12(4):279-287 (1991).
[cited by applicant]
Grynkiewicz et at., “A new generation of Ca2+ indicators with greatly improved fluorescence properties,” Journal of Biological Chemistry, 260(6):3440-3345 (1985).
[cited by applicant]
Gunatilaka et al., “Bioactive ergost-5-ene-3 beta, 7 alpha-diol derivatives from
[cited by applicant]
Guthrie et al., “Morphological and biochemical differences expressed in separate dissociated cell cultures of dorsal and ventral halves of the mouse spinal cord,” Brain Research, 420(2):313-323 (1987).
[cited by applicant]
Hoeve et al., “The design of resolving agents. Chiral cyclic phosphoric acids,” Journal of Organic Chemistry, 50(23):4508-4514 (1985).
[cited by applicant]
Hoffmeister et al., “Zur chemie des ecdysons, III: Vergleichende spektrometrische untersuchungen an a.b-ungesättigten steroidketonen,” Chemische Berichte, 98(7):2361-2375 (1965).
[cited by applicant]
Hogg et al., “An automated system for intracellular and intranuclear injection,” Journal of Neuroscience, Methods, 169(1):65-75 (2008).
[cited by applicant]
Hollmann et al., “Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor,” Neuron, 10(5):943-954 (1993).
[cited by applicant]
Horak et al., “Molecular mechanism of pregnenolone sulfate action at NR1/NR2B receptors,” Journal of Neuroscience, 24(46):10318-10325 (2004).
[cited by applicant]
Huttunen et al., “Prodrugs—from serendipity to rational design,” Pharmacological Reviews, 63(3):750-771 (2011).
[cited by applicant]
Iida et al., “An improved method for the capillary gas chromatographic derivatization of polyhydroxylated steroids having tert-hydroxyl groups,” Analytical Sciences, 19(9):1317-1321 (2003).
[cited by applicant]
Irwin et al., “Steroid potentiation and inhibition of N-methyl-D-aspartate receptor-mediated intracellular Ca++ responses: structure-activity studies,” Journal of Pharmacology and Experimental Therapeutics, 271(2):677-6…
[cited by applicant]
Jack et al., “Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade,” Lancet Neurology, 9(1):119-128 (2010).
[cited by applicant]
Jack et al., “Introduction to the recommendations from the National Institute on Aging—Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's & Dementia, 7(3):257-62 (2011).
[cited by applicant]
Jurman et al., “Visual identification of individual transfected cells for electrophysiology using antibody-coated beads,” Biotechniques, 17(5):876-881 (1994).
[cited by applicant]
Karaki et al., “Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L 1) ligands identified by screening assay monitoring pharmacological chaperone effect,” Bioorganic and Medicinal Chemistry, 21…
[cited by applicant]
Khripach et al., “Synthesis of (24S)-hydroxy-and (24S)-24,25-epoxycholesterol analogues, potential agonists of nuclear LXR receptors,” Russian Journal of Bioorganic Chemistry, 32(6):586-594 (2006).
[cited by applicant]
Knoppert et al., “Position paper: Pediatric age categories to be used in differentiating between listing on a model essential medicines list for children,” pp. 1-5 (2007).
[cited by applicant]
Kurosawa et al., “Synthesis of 19-hydroxylated bile acids and identification of 3 alpha, 7 alpha, 12 alpha, 19-tetrahydroxy-5 beta-cholan-24oic acid in human neonatal urine,” Chemical and Pharmaceutical Bulletin, 43(9):…
[cited by applicant]
Lakhan et al., “NMDA receptor activity in neuropsychiatric disorders,” Frontiers in Psychiatry, 4:1-7 (2013).
[cited by applicant]
Lala et al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors,” Cancer and Metastasis Reviews, 17(1):91-106 (1998).
[cited by applicant]
Layzer, “Section five-degenerative diseases of the nervous system,” Cecil Textbook of Medicine, 20th edition, 2:2050-2057 (1996).
[cited by applicant]
Leoni et al., “Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis,” Neuroscience Letters, 331(3):163-166 (2002).
[cited by applicant]
Leoni et al., “Oxysterols as biomarkers in neurodegenerative diseases,” Chemistry and Physics of Lipids, 164(6):515-524 (2011).
[cited by applicant]
Lettré et al., “Mehrwertige alkohole aus sterinen und sterinderivaten, VI Steroide mit strukturmerkmalen des ecdysons und der elatericine,” Justus Liebigs Annalen der Chemie, 758:89-110 (1972) (English Abstract).
[cited by applicant]
Li et al., “Synthesis of 7alpha-hydroxy derivatives of regulatory oxysterols,” Steroids, 65(9):529-535 (2000).
[cited by applicant]
Linsenbardt et al., “Different oxysterols have opposing actions at N-methyl-D-aspartate receptors,” Neuropharmacology, 85:232-242 (2014).
[cited by applicant]
Litvan et al., “Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines,” Movement Disorders, 27(3):349-56 (2012).
[cited by applicant]
Litvan et al., “MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI,” Movement Disorders, 26(10):1814-1824 (2011).
[cited by applicant]
Lutjohann et al., “Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation,” PNAS, 93(18):9799-804 (1996).
[cited by applicant]
Luu et al., “Oxysterols: Old Tale, New Twists,” Annual Review of Pharmacology and Toxicology, 56:447-467 (2016).
[cited by applicant]
Madau et al., Program No. 613.2/B87. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience (2009) (3 pages).
[cited by applicant]
Mateos et al., “Activity-regulated cytoskeleton-associated protein in rodent brain is down regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro,” Brain Pathology, 19(1):69-80 (2009).
[cited by applicant]
Meljon et al., “Analysis by liquid chromatography-mass spectrometry of sterols and oxysterols in brain of the newborn Dher7(Δ3-5/T93M) mouse: a model of Smith-Lemli-Opitz syndrome,” Biochemical Pharmacology, 86(1):43-55…
[cited by applicant]
Monyer et al., “Heteromeric NMDA receptors: molecular and functional distinction of subtypes,” Science, 256(5060):1217-1221 (1992).
[cited by applicant]
Mourino et al., “Studies on vitamin D (calciferol) and its analogs. 15. 24-nor-1a,25-dihydroxyvitamin D3 and 24-nor-25-hydroxy-5,6-trans-vitamin D3,” Journal of Medicinal Chemistry, 21(10):1025-1029 (1978).
[cited by applicant]
Nagano et al., “Chemistry and biochemistry of Chinese drugs. Part II. Hydroxylated sterols, cytotoxic towards cancerous cells: synthesis and testing,” Journal of Chemical Research, 9:218 (1977).
[cited by applicant]
Nagasaka et al., “Oxysterol changes along with cholesterol and vitamin D changes in adult phenylketonuric patients diagnosed by newborn mass-screening,” Clinica Chimica Acta, 416:54-59 (2013).
[cited by applicant]
Nasreddine et al., “The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment,” Journal of the American Geriatrics Society, 53(4):695-699 (2005).
[cited by applicant]
Niemann-Pick diagnosis-treatment [online] retrieved from the internet on Jul. 17, 2021 (URL: https://www.mayoclinic.org/diseases-conditions/niemann-pick/diagnosis-treatment/drc-20355890) (2 pages).
[cited by applicant]
Niemann-Pick overview [online] retrieved from the internet on Jul. 17, 2021 (URL: https://www.mayoclinic.org/diseases-conditions/niemann-pick/symptoms-causes/syc-20355887) (4 pages).
[cited by applicant]
Olkkonen et al., “Oxysterols and their cellular effectors,” Biomolecules, 2(1):76-103 (2012).
[cited by applicant]
Papassotiropoulos, et al., “Plasma 24S-hydroxycholesterol a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease”, NeuroReport 11(9): 1959-1962 (2000).
[cited by applicant]
Park-Chung et al., “Distinct sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated steroids,” Molecular Pharmacology, 52(6):1113-1123 (1997).
[cited by applicant]
Paul et al., “The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent Allosteric modulator of N-methyl-D-aspartate receptors,” The Journal of Neuroscience, 33(44):17290-17300 (2013).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2012/054261, dated Nov. 28, 2012 (10 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2014/026633, dated Jul. 14, 2014 (6 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2014/026784, dated Jul. 8, 2014 (13 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2015/036510, dated Sep. 15, 2015 (7 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2015/054551, dated Jan. 8, 2016 (10 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2016/041160, dated Oct. 28, 2016 (7 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2016/041168, dated Sep. 15, 2016 (6 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2016/041175, dated Sep. 16, 2016 (6 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2017/025535, dated Jul. 3, 2017 (7 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2017/031374, dated Aug. 14, 2017 (8 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2017/041199, dated Aug. 29, 2017 (12 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2017/054657, dated Nov. 21, 2017 (18 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2017/057276, dated Dec. 11, 2017 (13 pages).
[cited by applicant]
PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2017/057277, dated Feb. 20, 2018 (19 pages).
[cited by applicant]
PCT Invitation to Correct Fees and Partial International Search Report and Provisional Opinion for corresponding International Application No. PCT/US2017/057277, dated Dec. 20, 2017 (13 pages).
[cited by applicant]
Petrovic et al., “Pregnenolone sulfate modulation of N-methyl-D-aspartate receptors is phosphorylation dependent,” Neuroscience, 160:616-628 (2009).
[cited by applicant]
Pritchett et al., “Transient expression shows ligand gating and allosteric potentiation of GABAA receptor subunits,” Science, 242(4883):1306-1308 (1988).
[cited by applicant]
Pubchem, CID 00065094, 25-Hydroxycholesterol, Nov. 18, 2016 (17 pages).
[cited by applicant]
Pubchem, CID 0132021, Ergostan-3,24-diol, Mar. 5, 2018 (15 pages).
[cited by applicant]
Pubchem, CID 54083335, Schemb14961477, Nov. 8, 2016 (13 pages).
[cited by applicant]
Pubchem, CID 54160779, Schemb14961477, Nov. 8, 2016 (13 pages).
[cited by applicant]
Pubchem, CID 58455549, Schembl12198161, Nov. 8, 2016 (13 pages).
[cited by applicant]
Pubchem, CID 66966798, Cholane-3alpha,24,-diol, Nov. 8, 2016 (11 pages).
[cited by applicant]
Pubchem, CID 70604305, Schembl11528874, Nov. 8, 2016 (13 pages).
[cited by applicant]
Pubchem, CID 71508953, Mar. 5, 2018 (13 pages).
[cited by applicant]
Reddy, “Pharmacology of endogenous neuroactive steroids,” Critical Reviews in Neurobiology, 15(3-4):197-234 (2013).
[cited by applicant]
Registry (STN) [online] CAS Registration No. 1392266-35-1; 13392266-34-0; 1271523-00-2; 185138-08-3; 185138-00-5; 1851387-82-0; 66450-87-1 (2012).
[cited by applicant]
Roh et al., “Neuroprotective effects of ginsenoside Rg3 against 24-OH-cholesterol-induced cytotoxicity in cortical neurons,” Journal of Ginseng Research, 34(3):246-253 (2010).
[cited by applicant]
Schmidt et al., “Inhibitory effect of oxygenated cholestan-3b-ol derivatives on the growth of Mycobacterium tuberculosis,” Bioorganic & Medicinal Chemistry Letters, 23(22):6111-6113 (2013).
[cited by applicant]
Segal, “Pat hippocampal Neurons in Culture: Responses to Electrical and Chemical Stimuli,” Journal of Neurophysiology, 50(6):1249-1264 (1983).
[cited by applicant]
Sepe et al., “Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity,” Journal of Medicinal Chemistry, 54:4590-4599 (…
[cited by applicant]
Solomon, et al., “Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease”, Neuroscience Letters 462(1): 89-93 (2009).
[cited by applicant]
Stamp et al., “Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs,” British Medical Journal 4(5831): 9-12 (1972).
[cited by applicant]
Stastna et al., “Synthesis of C3, C5, and C7 pregnane derivatives and their effect on NMDA receptor responses in cultured rat hippocampal neurons,” Steroids, 74(2):256-263 (2008).
[cited by applicant]
Steinrauf et al., “Synthesis and evaluation of sulfur-containing steroids against methylmercuric chloride toxicity,” Journal of Pharmaceutical Sciences, 67(12):1739-1743 (1978).
[cited by applicant]
Svoboda et al., “Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders,” American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160C(4): 285-294 (2012).
[cited by applicant]
Takahashi et al., “Stereochemistry of reduction of the C-24,25 double bond in the conversion of desmosterol into cholesterol,” Tetrahedron Letters, 44(2):341-344 (2003).
[cited by applicant]
Takano et al., “Simple synthesis of 3b,24-dihydroxychol-5-en-7-one by oxidative cleavage of the side chain of cholesterol,” Chemistry Letters, 14(8):1265-1266 (1985).
[cited by applicant]
Tierney et al., “Abnormalities of cholesterol metabolism in autism spectrum disorders,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 141B(6):666-668 (2006).
[cited by applicant]
Tomek et al., “NMDA receptor modulators in the treatment of drug addiction,” Pharmaceuticals (Basel), 6(2):251-258 (2013).
[cited by applicant]
Verdoorn et al., “Functional properties of recombinant rat GABAA receptors depend upon subunit composition,” Neuron, 4(6):919-928 (1990).
[cited by applicant]
Vyklicky et al., “Calcium-mediated modulation of N-methyl-D-aspartate (NMDA) responses in cultured rat hippocampal neurones,” Journal of Physiology, 470:575-600 (1993).
[cited by applicant]
Wieland et al., “Comparative behavioral characterization of the neuroactive steroids 3 alpha-OH,5 alpha-pregnan-20-one and 3 alpha-OH,5 beta-pregnan-20-one in rodents,” Psychopharmacology 118(1):65-71 (1995).
[cited by applicant]
Wilen et al., “Strategies in Optical Resolutions,” Tetrahedron, 33:2725-2736 (1977).
[cited by applicant]
Wolozin et al., “The cellular biochemistry of cholesterol and statins: Insights into the pathophysiology and therapy of Alzheimer's disease,” CNS Drug Review, 10(2):127-146 (2004).
[cited by applicant]
Wong et al., “An efficient and convenient transformation of a-haloketones to a-hydroxyketones using cesium formate,” Journal of Organometallic Chemistry, 694(21):3452-3455 (2004).
[cited by applicant]
Xiangdong et al., “Highly stereoselective synthesis of 24R,25- and 24S, 25-dihydroxysteroid,” Database Chemical Abstracts Service, Database accession No. 2001:174431 (2000) (4 pages).
[cited by applicant]
Xilouri et al., “Neuroprotective effects of steroid analogues on P19-N neurons,” Neurochemistry International, 50(4):660-670 (2007).
[cited by applicant]
Yan et al., “Characterization of a synthetic steroid 24-keto-cholest-5-en-3b, 19-diol as a neuroprotectant,” CNS Neuroscience & Therapeutics, 21(6):486-495 (2015).
[cited by applicant]
Yang et al., “New cytotoxic oxygenated sterols from marine bryozoan
[cited by applicant]
Zhou et al., “Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature,” Biophysical Journal, 74(1):230-241 (1998).
[cited by applicant]
Zuliani et al., “Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study,” BMC Neurology 11(121): 1-8 (2011).
[cited by applicant]
U.S. Appl. No. 14/343,603, filed Nov. 25, 2014, Abandoned.
[cited by applicant]
U.S. Appl. No. 14/775,401, filed Sep. 11, 2015, Abandoned.
[cited by applicant]
U.S. Appl. No. 14/775,678, filed Sep. 12, 2015, Abandoned.
[cited by applicant]
U.S. Appl. No. 15/319,504, filed Dec. 16, 2016, U.S. Pat. No. 10,259,840, Apr. 16, 2019. Issued.
[cited by applicant]
U.S. Appl. No. 15/517,886, filed Apr. 7, 2017, Abandoned.
[cited by applicant]
U.S. Appl. No. 15/588,305, filed May 5, 2017, Abandoned.
[cited by applicant]
U.S. Appl. No. 15/742,422, filed Jan. 5, 2018, U.S. Pat. No. 10,696,712, Jun. 30, 2020, Issued.
[cited by applicant]
U.S. Appl. No. 15/742,424, filed Jan. 5, 2018, U.S. Pat. No. 11,117,924, Sep. 14, 2021, Issued.
[cited by applicant]
U.S. Appl. No. 15/742,425, filed Jan. 5, 2018, U.S. Pat. No. 10,201,550, Feb. 12, 2019, Issued.
[cited by applicant]
U.S. Appl. No. 15/917,263, filed Mar. 9, 2018, U.S. Pat. No. 10,227,375, Mar. 12, 2019, Issued.
[cited by applicant]
U.S. Appl. No. 15/917,272, filed Mar. 9, 2018, Abandoned.
[cited by applicant]
U.S. Appl. No. 16/028,790, filed Jul. 6, 2018, U.S. Pat. No. 10,723,758, Jul. 28, 2020.
[cited by applicant]
U.S. Appl. No. 16/089,896, filed Sep. 28, 2018, Abandoned.
[cited by applicant]
U.S. Appl. No. 16/099,122, filed Nov. 5, 2018, U.S. Pat. No. 10,752,653, Aug. 25, 2020, Issued.
[cited by applicant]
U.S. Appl. No. 16/114,791, filed Aug. 28, 2018, U.S. Pat. No. 10,759,828, Sep. 1, 2020, Issued.
[cited by applicant]
U.S. Appl. No. 16/227,013, filed Dec. 20, 2018, U.S. Pat. No. 11,104,701, Aug. 31, 2021, Issued.
[cited by applicant]
U.S. Appl. No. 16/227,099, filed Dec. 20, 2018, U.S. Pat. No. 10,765,685, Sep. 8, 2020, Issued.
[cited by applicant]
U.S. Appl. No. 16/315,250, filed Jan. 4, 2019, U.S. Pat. No. 10,781,231, Sep. 22, 2020, Issued.
[cited by applicant]
U.S. Appl. No. 16/338,315, filed Mar. 29, 2019, U.S. Pat. No. 11,149,056, Oct. 19, 2021, Issued.
[cited by applicant]
U.S. Appl. No. 16/343,235, filed Apr. 18, 2019, U.S. Pat. No. 11,149,054, Oct. 19, 2021, Issued.
[cited by applicant]
U.S. Appl. No. 16/343,238, filed Apr. 18, 2019, U.S. Pat. No. 11,111,266, Sep. 7, 2021, Issued.
[cited by applicant]
U.S. Appl. No. 16/879,460, filed May 20, 2020, Abandoned.
[cited by applicant]
U.S. Appl. No. 16/902,730, filed Jun. 16, 2020, Abandoned.
[cited by applicant]
U.S. Appl. No. 16/930,047, filed Jul. 15, 2020, U.S. Pat. No. 11,407,782, Aug. 9, 2022, Issued.
[cited by applicant]
U.S. Appl. No. 16/938,348, filed Jul. 24, 2020, Abandoned.
[cited by applicant]
U.S. Appl. No. 16/942,235, filed Jul. 29, 2020, Abandoned.
[cited by applicant]
U.S. Appl. No. 16/942,245, filed Jul. 29, 2020, Abandoned.
[cited by applicant]
U.S. Appl. No. 16/943,649, filed Jul. 30, 2020, U.S. Pat. No. 11,279,730, Mar. 22, 2022, Issued.
[cited by applicant]
U.S. Appl. No. 17/242,860, filed Apr. 28, 2021, U.S. Pat. No. 11,884,697, Jan. 30, 2024, Issued.
[cited by applicant]
U.S. Appl. No. 17/381,829, filed Jul. 21, 2021, U.S. Pat. No. 11,905,309, Feb. 20, 2024, Issued.
[cited by applicant]
U.S. Appl. No. 17/386,364, filed Jul. 27, 2021, U.S. Pat. No. 11,613,556, Mar. 28, 2023, Issued.
[cited by applicant]
U.S. Appl. No. 17/395,155, filed Aug. 5, 2021, U.S. Pat. No. 11,851,457, Dec. 26, 2023, Issued.
[cited by applicant]
U.S. Appl. No. 17/396,034, filed Aug. 6, 2021, U.S. Pat. No. 11,732,000, Aug. 22, 2023, Issued.
[cited by applicant]
U.S. Appl. No. 17/707,303, filed Mar. 29, 2022, U.S. Pat. No. 12,129,275, Oct. 29, 2024, Issued.
[cited by applicant]
U.S. Appl. No. 17/749,976, filed May 20, 2022, Abandoned.
[cited by applicant]
U.S. Appl. No. 17/860,816, filed Jul. 8, 2022, U.S. Pat. No. 11,878,995, Jan. 23, 2024, Issued.
[cited by applicant]
U.S. Appl. No. 17/947,844, filed Sep. 19, 2022, Pending.
[cited by applicant]
U.S. Appl. No. 18/077,031, filed Dec. 7, 2022, Pending.
[cited by applicant]
U.S. Appl. No. 18/106,073, filed Feb. 6, 2023, Pending.
[cited by applicant]
U.S. Appl. No. 18/116,557, filed Mar. 2, 2023, U.S. Pat. No. 12,129,276, Oct. 29, 2024, Issued.
[cited by applicant]
U.S. Appl. No. 18/216,057, filed Jun. 29, 2023, Pending.
[cited by applicant]
U.S. Appl. No. 18/289,550, filed Nov. 3, 2023, Pending.
[cited by applicant]
U.S. Appl. No. 18/388,390, filed Nov. 9, 2023, Pending.
[cited by applicant]
U.S. Appl. No. 18/405,657, filed Jan. 5, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/430,056, filed Feb. 1, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/532,752, filed Dec. 7, 2023, Pending.
[cited by applicant]
U.S. Appl. No. 18/535,256, filed Dec. 11, 2023, Pending.
[cited by applicant]
U.S. Appl. No. 18/568,624, filed Dec. 8, 2023, Pending.
[cited by applicant]
U.S. Appl. No. 18/685,603, filed Feb. 22, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/694,572, filed Mar. 22, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/719,143, filed Jun. 12, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/719,194, filed Jun. 12, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/746,388, filed Jun. 18, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/813,962, filed Aug. 23, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/813,999, filed Aug. 23, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/814,031, filed Aug. 23, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/814,049, filed Aug. 23, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/893,387, filed Sep. 23, 2024, Pending.
[cited by applicant]
U.S. Appl. No. 18/893,565, filed Sep. 23, 2024, Pending.
[cited by applicant]
Bjorkhem et al., “Oxysterols and Alzheimer's disease,” Acta Neurologica Scandinavica, 114(Suppl. 195):43-49 (2006).
[cited by applicant]
Eguchi et al., “Synthesis and determination of configuration of natural 25-hydroxyvitamin D3 26,23-lactone,” PNAS, 78 (11):6579-6583 (1981).
[cited by applicant]
Eguchi et al., “Synthesis of Four Isomers of 25-Hydroxyvitamin D3-26,23-Lactone,” Hetercyles, 17:359-375 (1982).
[cited by applicant]
Guntert et al., “Synthese eines homologen steroidischen 17 -Pyrrolinons Partialsynthetische Versuche in der Reihe der Herzgifte, 9. Mitteilung,” Helvetica Chimica Acta, 59(6)2138-2148 (1976).
[cited by applicant]
Koizumi et al., “Stereoselective Introduction of Hydroxy Groups into the Cholesterol Side Chain. Preparation of (24R)- and (24S)-24,25-Dihydroxy- and (25R)- and (25S)-25,26-Dihydroxyvitamin D3 by Asymmetric Synthesis,” …
[cited by applicant]
Koldamova et al., “22R-Hydroxycholesterol and 9-cis-Retinoic Acid Induce ATP-binding Cassette Transporter A1 Expression and Cholesterol Efflux in Brain Cells and Decrease Amyloid ß Secretion,” Journal of Biological Chem…
[cited by applicant]
Matsumori et al., “An amphotericin B-ergosterol covalent conjugate with powerful membrane permeabilizing activity,” Chemistry & Biology, 11(5):673-679 (2004).
[cited by applicant]
Morisaki et al., “Nutritional effect of possible intermediates of phytosterol dealkylation in the silkworm,
[cited by applicant]
Segatto, et al., “Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline”, Current Medicinal Chemistry 21(1):1-15 (2014).
[cited by applicant]
Schubring et al., “The bile steroid chenodeoxycholate is a potent antagonist at NMDA and GABAA receptors,” Neuroscience Letters, 506(2):322-326 (2012).
[cited by applicant]
Cited By (1)